-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 29, Huadong Pharmaceutical announced that its wholly-owned subsidiary Hangzhou Sino-American Huadong Pharmaceutical Co.
TTP273 is an oral small molecule non-peptide GLP-1 receptor agonist for the treatment of type 2 diabetes
According to the agreement, Huadong Medicine will receive a down payment of US$1.
Huadong Medicine is currently conducting Phase 2 clinical trials of TTP273 in China and Taiwan
Huadong Medicine and Daewon will jointly establish a joint steering committee.